EUVIMEDAvasta EUVIMED
CrossrefInfokaart

Metabolomic analysis reveals the molecular mechanism related to leg abnormality in broilers

Jumei Zheng, Qi Zhang, Xinxin Tang, Fan Ying, Dawei Liu, Sen Li, Ranran Liu, Jie Wen, QingHe Li, Guiping Zhao

Animal Research and One Health · 2025-11 · 3 (4) · 368-378

DOI: 10.1002/aro2.63 ↗
AbstraktBibliograafilised andmed

Abstrakt

Abstract Rapid body weight gain in broilers overloads the metabolic system of the organism, resulting in leg abnormalities, which seriously affects animal welfare and industry economics. In this study, broilers with normal and deformed leg bones were examined. Serum biochemical indices showed that the serum calcium to phosphorus ratio was extremely decreased in leg deformed group. In addition, abnormal serum lipid levels suggested a disruption in lipid metabolism. Based on widely targeted metabonomic analysis of serum and cartilage tissues, a total of nine differential metabolites (DMs) significantly associated with leg abnormalities and serum calcium and phosphorus levels were screened, including carnitine C16:0, carnitine C18:1, 3‐hydroxymethyl‐L‐tyrosine, cis‐4‐hydroxy‐D‐proline, cis‐L‐3‐hydroxyproline, trans‐4‐hydroxy‐L‐proline, and so on. Pathway analysis revealed that fatty acid degradation and arachidonic acid metabolism were enriched. Analysis of DMs in these two pathways showed that prostaglandin D 2 , prostaglandin J 2 , prostaglandin A 2 , 15‐keto prostaglandin F 2α, and Δ12‐prostaglandin J 2 significantly differed between the normal and abnormal groups. It was hypothesized that these important metabolic pathways and metabolites were involved in the metabolic regulation of leg abnormalities.

Teadmised, mis sobivad teie tööga.

Tasuta alustamisest ja isiklikust kirjanduse otsingust kuni täieliku Research Suite’ini.

Vaata pakette →

Kas kõik kirjastajate täistekstid on kaasatud?

Ei. Bibliograafilised kirjed, kokkuvõtted ja täistekstid on erinevad sisud. See, kas täistekst on saadaval, sõltub allikast, Open Accessist ja teie olemasolevatest litsentsidest. EUVIMED-i pakett ei asenda täiendavaid kirjastajaõigusi.

Vaata pakette →